Rapid Whole-Genome Sequencing in Dubai Changed Clinical Management for 53 of 100 Critically Ill Children
Background
Dubai’s rapid whole-genome sequencing (rWGS) program, Little Falcon, affected inpatient clinical management for 53 of 100 critically ill children suspected of having a genetic disorder. The genetic cause was identified in 53% as well, but diagnostic yield and management changes are distinct outcomes.
In intensive care, genetic disorders can present with symptoms shared by many conditions, such as seizures or metabolic abnormalities. Sequential testing can take weeks or longer to identify a cause, limiting its usefulness for acute treatment decisions. The burden of recessive genetic disorders is high in the Middle East, but establishing genomic analysis infrastructure and securing specialist staff have been barriers to adoption. The research team connected neonatal and pediatric intensive care units across Dubai Health, the city’s public healthcare system, to assess the effect of rapid diagnosis on clinical care.
Key findings
The study included 100 children suspected of having a genetic disorder for whom rapid diagnosis was considered likely to help acute management. Sixty-two were referred from neonatal intensive care and 38 from pediatric intensive care; the median age at evaluation was 17 days. In 98 cases, the child and both parents were analyzed; in two, the child and mother were analyzed without a paternal sample.
A molecular diagnosis explaining the primary symptoms was made in 53 children, for a diagnostic yield of 53% (95% confidence interval, 43.3–62.5%). Among patients whose genomic analysis suggested close parental relatedness, 28 of 35 (80%) received a diagnosis. The diagnostic yield was separately also 80% in the group referred primarily for metabolic disease evaluation. Dual molecular diagnoses, in which two genetic disorders contributed to symptoms, were found in 5% of the cohort. Multiple molecular findings, including additional findings unrelated to the primary disorder, were found in 12%; these are distinct from dual diagnoses.
The median time from sample submission to result reporting was 81.1 hours, or about 3.4 days. The researchers compared these results with those for 100 historical patients who received standard genetic testing before the program, between 2018 and 2022. The historical control group had a median turnaround time of 38 days, a diagnostic yield of 30%, and a clinical management change rate of 18%. The corresponding figures in the rWGS group were 3.4 days, 53%, and 53%.
The 53 patients whose management changed included 45 who received a molecular diagnosis and eight who did not. The assessment covered medication or dietary adjustments during intensive care, refinement of the testing pathway, decisions about procedures or surgery, specialist referrals, and palliative care decisions. Medication or dietary interventions were reported in 36% of the full cohort, and procedure- or surgery-related decisions in 13%; these categories could overlap.
The researchers also reported immediate changes in disease course following management plans in 16% of all patients. This comprised 8% with recorded favorable outcomes and 8% with end-of-life decisions. This does not establish improved survival or a treatment success rate of 16%.
Meaning and outlook
The study highlights the value of an operational system that connects referrals, genetic counseling, variant interpretation, and delivery of results, alongside testing speed. A multidisciplinary team jointly selected patients for testing, and results were sent to the clinical team as soon as analysis was complete. The researchers interpreted this system as supporting integration of rWGS into the initial diagnostic pathway in intensive care.
However, the study used a historical control comparison rather than a randomized trial with concurrent controls, so the observed differences cannot all be attributed to the introduction of the test. Results in this selected group of children suspected of having a genetic disorder cannot be applied directly to all critically ill children. Limited genomic reference data for Middle Eastern populations also constrain variant interpretation. The study did not directly establish improved survival or conduct a formal cost-effectiveness analysis; other healthcare systems should assess clinical outcomes and operating costs together when considering adoption.
The study population, results, and operational process are described in the publicly available full text of the Nature Medicine article.
Nature Medicine, Published online: 24 August 2026; doi:10.1038/s41591-026-04598-xLittle Falcon, a citywide rapid whole-genome sequencing program implemented within centralized neonatal and pediatric intensive care units within the Dubai healthcare system, led to clinically meaningful shifts in care trajectory in 53% of patients.
A practical example involved a 2-month-old infant with Wolman disease. The child had abdominal distension, adrenal calcification, and a worsening condition. rWGS diagnosed Wolman disease in 50.6 hours, identifying a homozygous exonic deletion in the LIPA gene. Clinicians were able to start enzyme replacement therapy and adjust the diet before conventional biochemical testing was complete. The paper reports that the clinical course stabilized after early treatment, but this single case cannot establish the magnitude of any survival benefit.
Hospitals need a system that can interpret results and connect them to treatment decisions, as well as sequencing equipment. The program’s referral network, genetic counseling, and rapid communication between the laboratory and clinical teams may inform implementation at other institutions. Diagnostic yield and actual management changes should be tracked separately to assess clinical value.